Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?

Inzucchi SE, Fitchett D, Jurišić-Eržen D, Woo V, Hantel S, Janista C, Kaspers S, George JT, Zinman B; EMPA-REG OUTCOME® Investigators.

Diabetes Obes Metab. 2019 Dec 2. doi: 10.1111/dom.13938. [Epub ahead of print]

PMID:
31789445
2.

A Clinical Risk Model to Predict Obstetric Anal Sphincter Injuries in Laboring Patients.

Woo VG, Hung YY, Ritterman-Weintraub ML, Painter CE, Ramm O.

Female Pelvic Med Reconstr Surg. 2019 Sep 6. doi: 10.1097/SPV.0000000000000777. [Epub ahead of print]

PMID:
31498241
3.

Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol.

Goldenberg RM, Gilbert JD, Hramiak IM, Woo VC, Zinman B.

Diabetes Obes Metab. 2019 Oct;21(10):2192-2202. doi: 10.1111/dom.13811. Epub 2019 Jun 30. Review.

PMID:
31183975
4.

Microbiota Inhibit Epithelial Pathogen Adherence by Epigenetically Regulating C-Type Lectin Expression.

Woo V, Eshleman EM, Rice T, Whitt J, Vallance BA, Alenghat T.

Front Immunol. 2019 May 7;10:928. doi: 10.3389/fimmu.2019.00928. eCollection 2019.

5.

CANadian CAnagliflozin REgistry: Patient-Reported Outcomes of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Canadian Clinical Practice.

Woo V, Bell A, Clement M, Noronha L, Tsoukas MA, Camacho F, Traina S, Georgijev N, Rose JB, Sorabji D, Bajaj HS.

Can J Diabetes. 2019 Oct;43(7):464-471. doi: 10.1016/j.jcjd.2019.04.004. Epub 2019 Apr 16.

PMID:
31133438
6.

Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).

Pollock RF, Heller S, Pieber TR, Woo V, Gundgaard J, Hallén N, Luckevich M, Tutkunkardas D, Zinman B; DEVOTE Study Group.

Diabetes Obes Metab. 2019 Jul;21(7):1706-1714. doi: 10.1111/dom.13730. Epub 2019 Apr 14.

7.

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.

Zinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D, Thrasher J, Woo V, Philis-Tsimikas A.

Lancet Diabetes Endocrinol. 2019 May;7(5):356-367. doi: 10.1016/S2213-8587(19)30066-X. Epub 2019 Mar 1. Erratum in: Lancet Diabetes Endocrinol. 2019 Mar 11;:. Lancet Diabetes Endocrinol. 2019 Aug;7(8):e20. Lancet Diabetes Endocrinol. 2019 Nov;7(11):e22.

PMID:
30833170
8.

The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.

Woo V, Connelly K, Lin P, McFarlane P.

Curr Med Res Opin. 2019 Jul;35(7):1283-1295. doi: 10.1080/03007995.2019.1576479. Epub 2019 Feb 15.

PMID:
30767677
9.

Combined Atropine with Orthokeratology for Myopia Control: Study Design and Preliminary Results.

Tan Q, Ng AL, Cheng GP, Woo VC, Cho P.

Curr Eye Res. 2019 Jun;44(6):671-678. doi: 10.1080/02713683.2019.1568501. Epub 2019 Jan 24.

PMID:
30632410
10.

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.

Aroda VR, Ahmann A, Cariou B, Chow F, Davies MJ, Jódar E, Mehta R, Woo V, Lingvay I.

Diabetes Metab. 2019 Oct;45(5):409-418. doi: 10.1016/j.diabet.2018.12.001. Epub 2019 Jan 4. Review.

PMID:
30615985
11.

Gabapentin and pregabalin to treat aggressivity in dementia: a systematic review and illustrative case report.

Supasitthumrong T, Bolea-Alamanac BM, Asmer S, Woo VL, Abdool PS, Davies SJC.

Br J Clin Pharmacol. 2019 Apr;85(4):690-703. doi: 10.1111/bcp.13844. Epub 2019 Feb 8. Review.

PMID:
30575088
12.

Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis.

Castellanos JG, Woo V, Viladomiu M, Putzel G, Lima S, Diehl GE, Marderstein AR, Gandara J, Perez AR, Withers DR, Targan SR, Shih DQ, Scherl EJ, Longman RS.

Immunity. 2018 Dec 18;49(6):1077-1089.e5. doi: 10.1016/j.immuni.2018.10.014. Epub 2018 Dec 11.

PMID:
30552020
13.

Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis.

Bowering K, Rodbard HW, Russell-Jones D, Bode B, Harris S, Piletic M, Heller S, Woo V, Babu V, Dethlefsen C, Mathieu C.

Diabetes Ther. 2019 Feb;10(1):177-188. doi: 10.1007/s13300-018-0553-7. Epub 2018 Dec 13.

14.

CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice.

Woo V, Bell A, Clement M, Noronha L, Tsoukas MA, Camacho F, Traina S, Georgijev N, Culham MD, Rose JB, Rapattoni W, Bajaj HS.

Diabetes Obes Metab. 2019 Mar;21(3):691-699. doi: 10.1111/dom.13573. Epub 2018 Dec 5.

15.

CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management.

Mancini GBJ, Cheng AY, Connelly K, Fitchett D, Goldenberg R, Goodman S, Leiter LA, Lonn E, Paty B, Poirier P, Stone J, Thompson D, Verma S, Woo V, Yale JF.

Can J Cardiol. 2018 Oct;34(10):1350-1361. doi: 10.1016/j.cjca.2018.07.010. Epub 2018 Jul 19. Review.

16.

Erratum to "Diabetes and Driving": Canadian Journal of Diabetes 2018;42(S1):S150-S153.

Houlden RL, Berard L, Lakoff JM, Woo V, Yale JF.

Can J Diabetes. 2018 Oct;42(5):576. doi: 10.1016/j.jcjd.2018.08.196. No abstract available.

PMID:
30268232
17.

Microbiota-sensitive epigenetic signature predicts inflammation in Crohn's disease.

Kelly D, Kotliar M, Woo V, Jagannathan S, Whitt J, Moncivaiz J, Aronow BJ, Dubinsky MC, Hyams JS, Markowitz JF, Baldassano RN, Stephens MC, Walters TD, Kugathasan S, Haberman Y, Sundaram N, Rosen MJ, Helmrath M, Karns R, Barski A, Denson LA, Alenghat T.

JCI Insight. 2018 Sep 20;3(18). pii: 122104. doi: 10.1172/jci.insight.122104. eCollection 2018 Sep 20.

18.

Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme.

DeVries JH, Desouza C, Bellary S, Unger J, Hansen OKH, Zacho J, Woo V.

Diabetes Obes Metab. 2018 Oct;20(10):2426-2434. doi: 10.1111/dom.13396. Epub 2018 Jul 9.

19.

Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children.

Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Padwal RS, Tran KC, Grover S, Rabkin SW, Moe GW, Howlett JG, Lindsay P, Hill MD, Sharma M, Field T, Wein TH, Shoamanesh A, Dresser GK, Hamet P, Herman RJ, Burgess E, Gryn SE, Grégoire JC, Lewanczuk R, Poirier L, Campbell TS, Feldman RD, Lavoie KL, Tsuyuki RT, Honos G, Prebtani APH, Kline G, Schiffrin EL, Don-Wauchope A, Tobe SW, Gilbert RE, Leiter LA, Jones C, Woo V, Hegele RA, Selby P, Pipe A, McFarlane PA, Oh P, Gupta M, Bacon SL, Kaczorowski J, Trudeau L, Campbell NRC, Hiremath S, Roerecke M, Arcand J, Ruzicka M, Prasad GVR, Vallée M, Edwards C, Sivapalan P, Penner SB, Fournier A, Benoit G, Feber J, Dionne J, Magee LA, Logan AG, Côté AM, Rey E, Firoz T, Kuyper LM, Gabor JY, Townsend RR, Rabi DM, Daskalopoulou SS; Hypertension Canada.

Can J Cardiol. 2018 May;34(5):506-525. doi: 10.1016/j.cjca.2018.02.022. Epub 2018 Mar 1.

PMID:
29731013
20.

Disruption of Epithelial HDAC3 in Intestine Prevents Diet-Induced Obesity in Mice.

Whitt J, Woo V, Lee P, Moncivaiz J, Haberman Y, Denson L, Tso P, Alenghat T.

Gastroenterology. 2018 Aug;155(2):501-513. doi: 10.1053/j.gastro.2018.04.017. Epub 2018 Apr 22.

21.

Monitoring Glycemic Control.

Diabetes Canada Clinical Practice Guidelines Expert Committee, Berard LD, Siemens R, Woo V.

Can J Diabetes. 2018 Apr;42 Suppl 1:S47-S53. doi: 10.1016/j.jcjd.2017.10.007. No abstract available.

PMID:
29650111
22.

Treatment of Hypertension.

Diabetes Canada Clinical Practice Guidelines Expert Committee, Tobe SW, Gilbert RE, Jones C, Leiter LA, Prebtani APH, Woo V.

Can J Diabetes. 2018 Apr;42 Suppl 1:S186-S189. doi: 10.1016/j.jcjd.2017.10.011. No abstract available.

PMID:
29650094
23.

Diabetes and Driving.

Diabetes Canada Clinical Practice Guidelines Expert Committee, Houlden RL, Berard L, Lakoff JM, Woo V, Yale JF.

Can J Diabetes. 2018 Apr;42 Suppl 1:S150-S153. doi: 10.1016/j.jcjd.2017.10.018. No abstract available. Erratum in: Can J Diabetes. 2018 Oct;42(5):576.

PMID:
29650088
24.

In-Hospital Management of Diabetes.

Diabetes Canada Clinical Practice Guidelines Expert Committee, Malcolm J, Halperin I, Miller DB, Moore S, Nerenberg KA, Woo V, Yu CH.

Can J Diabetes. 2018 Apr;42 Suppl 1:S115-S123. doi: 10.1016/j.jcjd.2017.10.014. No abstract available.

PMID:
29650083
25.

Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting.

Seaquist ER, Dulude H, Zhang XM, Rabasa-Lhoret R, Tsoukas GM, Conway JR, Weisnagel SJ, Gerety G, Woo VC, Zhang S, Carballo D, Pradhan S, Piché CA, Guzman CB.

Diabetes Obes Metab. 2018 May;20(5):1316-1320. doi: 10.1111/dom.13278. Epub 2018 Mar 22.

26.

Sequential drug treatment algorithm for agitation and aggression in Alzheimer's and mixed dementia.

Davies SJ, Burhan AM, Kim D, Gerretsen P, Graff-Guerrero A, Woo VL, Kumar S, Colman S, Pollock BG, Mulsant BH, Rajji TK.

J Psychopharmacol. 2018 May;32(5):509-523. doi: 10.1177/0269881117744996. Epub 2018 Jan 17.

27.

Risk Factors for the Development of Obstetric Anal Sphincter Injuries in Modern Obstetric Practice.

Ramm O, Woo VG, Hung YY, Chen HC, Ritterman Weintraub ML.

Obstet Gynecol. 2018 Feb;131(2):290-296. doi: 10.1097/AOG.0000000000002444.

PMID:
29324610
28.

Caspase-6 is a Dispensable Enabler of Adult Mammalian Axonal Degeneration.

Woo V, Cheng C, Duraikannu A, Chandrasekhar A, Purdy K, Martinez JA, Zochodne DW.

Neuroscience. 2018 Feb 10;371:242-253. doi: 10.1016/j.neuroscience.2017.11.052. Epub 2017 Dec 8.

PMID:
29229552
29.

Comparing a new hydroexpression technique with conventional forceps method for SMILE lenticule removal.

Ng ALK, Cheng GPM, Woo VCP, Jhanji V, Chan TCY.

Br J Ophthalmol. 2018 Aug;102(8):1122-1126. doi: 10.1136/bjophthalmol-2017-310993. Epub 2017 Nov 9.

PMID:
29122820
30.

DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality.

Pieber TR, Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pratley RE, Woo V, Heller S, Lange M, Brown-Frandsen K, Moses A, Barner Lekdorf J, Lehmann L, Kvist K, Buse JB; DEVOTE Study Group.

Diabetologia. 2018 Jan;61(1):58-65. doi: 10.1007/s00125-017-4422-0. Epub 2017 Sep 15.

31.

Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin.

Yu H, Woo VC.

Diabetes Metab Syndr Obes. 2017 Jul 21;10:317-332. doi: 10.2147/DMSO.S117982. eCollection 2017. Review.

32.

Effect of the Learning Curve on Visual and Refractive Outcomes of Small-Incision Lenticule Extraction.

Chan TCY, Ng ALK, Cheng GPM, Woo VCP, Zhang J, Wang Y, Jhanji V.

Cornea. 2017 Sep;36(9):1044-1050. doi: 10.1097/ICO.0000000000001246.

PMID:
28644239
33.

Considerations for Initiating a Sodium-Glucose Co-Transporter 2 Inhibitor in Adults With Type 2 Diabetes Using Insulin.

Woo VC, Berard LD, Bajaj HS, Ekoé JM, Senior PA.

Can J Diabetes. 2018 Feb;42(1):88-93. doi: 10.1016/j.jcjd.2017.01.009. Epub 2017 May 31. Review.

PMID:
28579198
34.

Epithelial Histone Deacetylase 3 Instructs Intestinal Immunity by Coordinating Local Lymphocyte Activation.

Navabi N, Whitt J, Wu SE, Woo V, Moncivaiz J, Jordan MB, Vallance BA, Way SS, Alenghat T.

Cell Rep. 2017 May 9;19(6):1165-1175. doi: 10.1016/j.celrep.2017.04.046.

35.

Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults.

Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, Nerenberg K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tran KC, Tobe SW, Ruzicka M, Burns KD, Vallée M, Prasad GVR, Gryn SE, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E, Sivapalan P, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NRC, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Kline G, Leiter LA, Jones C, Côté AM, Woo V, Kaczorowski J, Trudeau L, Tsuyuki RT, Hiremath S, Drouin D, Lavoie KL, Hamet P, Grégoire JC, Lewanczuk R, Dresser GK, Sharma M, Reid D, Lear SA, Moullec G, Gupta M, Magee LA, Logan AG, Dionne J, Fournier A, Benoit G, Feber J, Poirier L, Padwal RS, Rabi DM; Hypertension Canada.

Can J Cardiol. 2017 May;33(5):557-576. doi: 10.1016/j.cjca.2017.03.005. Epub 2017 Mar 10. Erratum in: Can J Cardiol. 2017 Dec;33(12 ):1733-1734.

PMID:
28449828
36.

Single Delivery of High-Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative Colitis.

Jacob V, Crawford C, Cohen-Mekelburg S, Viladomiu M, Putzel GG, Schneider Y, Chabouni F, OʼNeil S, Bosworth B, Woo V, Ajami NJ, Petrosino JF, Gerardin Y, Kassam Z, Smith M, Iliev ID, Sonnenberg GF, Artis D, Scherl E, Longman RS.

Inflamm Bowel Dis. 2017 Jun;23(6):903-911. doi: 10.1097/MIB.0000000000001132.

37.

Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).

Russell-Jones D, Bode BW, De Block C, Franek E, Heller SR, Mathieu C, Philis-Tsimikas A, Rose L, Woo VC, Østerskov AB, Graungaard T, Bergenstal RM.

Diabetes Care. 2017 Jul;40(7):943-950. doi: 10.2337/dc16-1771. Epub 2017 Mar 29.

PMID:
28356319
38.

Birth Center Model of Care.

Woo VG, Milstein A, Platchek T.

JAMA. 2017 Feb 14;317(6):646. doi: 10.1001/jama.2016.20482. No abstract available.

PMID:
28196250
39.

A Review of the Clinical Efficacy and Safety of Insulin Degludec and Glargine 300 U/mL in the Treatment of Diabetes Mellitus.

Woo VC.

Clin Ther. 2017 Aug;39(8S2):S12-S33. doi: 10.1016/j.clinthera.2017.01.007. Epub 2017 Feb 7. Review.

PMID:
28187863
40.

IgA-coated E. coli enriched in Crohn's disease spondyloarthritis promote TH17-dependent inflammation.

Viladomiu M, Kivolowitz C, Abdulhamid A, Dogan B, Victorio D, Castellanos JG, Woo V, Teng F, Tran NL, Sczesnak A, Chai C, Kim M, Diehl GE, Ajami NJ, Petrosino JF, Zhou XK, Schwartzman S, Mandl LA, Abramowitz M, Jacob V, Bosworth B, Steinlauf A, Scherl EJ, Wu HJ, Simpson KW, Longman RS.

Sci Transl Med. 2017 Feb 8;9(376). pii: eaaf9655. doi: 10.1126/scitranslmed.aaf9655.

41.

Host-microbiota interactions: epigenomic regulation.

Woo V, Alenghat T.

Curr Opin Immunol. 2017 Feb;44:52-60. doi: 10.1016/j.coi.2016.12.001. Epub 2017 Jan 16. Review.

42.

Presbyopic Correction Using Monocular Bi-aspheric Ablation Profile (PresbyMAX) in Hyperopic Eyes: 1-Year Outcomes.

Chan TC, Kwok PS, Jhanji V, Woo VC, Ng AL.

J Refract Surg. 2017 Jan 1;33(1):37-43. doi: 10.3928/1081597X-20161006-03.

PMID:
28068445
43.

Achieving higher-value obstetrical care.

Woo VG, Lundeen T, Matula S, Milstein A.

Am J Obstet Gynecol. 2017 Mar;216(3):250.e1-250.e14. doi: 10.1016/j.ajog.2016.12.033. Epub 2016 Dec 29. Erratum in: Am J Obstet Gynecol. 2017 Jun;216(6):615.

PMID:
28041927
44.

Expansile radiolucency of the mandible.

Woo VL, McDonald MJ, Moxley JE.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 May;125(5):393-398. doi: 10.1016/j.oooo.2016.10.002. Epub 2016 Oct 12. No abstract available.

PMID:
28038976
45.

SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.

Goldenberg RM, Berard LD, Cheng AYY, Gilbert JD, Verma S, Woo VC, Yale JF.

Clin Ther. 2016 Dec;38(12):2654-2664.e1. doi: 10.1016/j.clinthera.2016.11.002. Review.

PMID:
28003053
46.

Effect of location of opening incision on astigmatic correction after small-incision lenticule extraction.

Chan TC, Ng AL, Cheng GP, Wang Z, Woo VC, Jhanji V.

Sci Rep. 2016 Oct 24;6:35881. doi: 10.1038/srep35881.

47.

Hospital-Affiliated Outpatient Birth Centers: A Possible Model for Helping to Achieve the Triple Aim in Obstetrics.

Woo VG, Milstein A, Platchek T.

JAMA. 2016 Oct 11;316(14):1441-1442. doi: 10.1001/jama.2016.11770. No abstract available.

PMID:
27727390
48.

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators.

N Engl J Med. 2016 Nov 10;375(19):1834-1844. Epub 2016 Sep 15.

50.

Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.

Mathieu C, Zinman B, Hemmingsson JU, Woo V, Colman P, Christiansen E, Linder M, Bode B; ADJUNCT ONE Investigators.

Diabetes Care. 2016 Oct;39(10):1702-10. doi: 10.2337/dc16-0691. Epub 2016 Aug 9.

PMID:
27506222

Supplemental Content

Support Center